News Archive

2020 Research Proposal Deadline EXTENDED

Due to the COVID-19 pandemic, the 2020 Answering TTP research grant competition deadline has been extended at least two months, until June 1, 2020. As the situation continues to evolve we will consider further extensions. Take care.

Caplacizumab is Approved by Health Canada

March 2, 2020: Caplacizumab has been approved by Health Canada for the treatment of adults with aTTP in combination with plasma echange and immunosuppressive therapy. Answering TTP Foundation is looking forward to working with provincial and territorial partners to ensure that this therapy is quickly made available at TTP treatment centers across the country and receives timely reimbursement by public and private plans.
 
Support Groups

Update on Pilot Program -- Virtual Peer Support Pilot Videoconference

The first Virtual Peer Support session was held on Jan 16, 2020 and was a success! We had a total of eight participants from Canada and the U.S.A., which made for some meaningful time to learn and share from each other. Participants included those diagnosed with TTP (both recently and dating back years) and family members.

Our next session will be help on March 19, 2020. Again, call in details will be circulated about a week prior to the date via Community Annoucement to the Answering TTP Community.

Industry aTTP Patient Focus Group Opportunity

A healthcare research firm is recruiting patients from accross Canada to share their experiences with aTTP. The purpose of this focus group will be to help a particular pharmaceutical company understand the aTTP journey and the types of support from which aTTP patients can benefit. Participation should take 2 hours, and compensation will be provided for participant's time.
 

2019 Funded Grant

Answering TTP Foundation had committed almost $2 million to research grants through 2021 thanks to our grass-roots fundraising campaigns like International TTP Day. The 2019 research competition attracted research proposals from North America and Europe. Proposals were peer reviewed by other TTP researchers and physicians. The winner was selected based on scientific merit.

ISTH Invites Public Comment on Draft TTP Guidelines

The ISTH welcomes the public to comment on its draft recommendations for the diagnosis and treatment of thrombotic thrombocytopenic purpura (TTP) via online survey only by October 21.

Answering TTP Foundation will submit feedback reviewed by a panel of patients and supporters. Clinicians, researchers, allied health professionals, policy makers, industry representatives, patients, caregivers, and other members of the public have been invited to contribute to this process.

Industry aTTP Patient Advisory Board Opportunity

A healthcare research firm is recruiting patients to assemble an advisory board of people living with an aTTP diagnosis. This advisory board will provide insight and feedback for the benefit of a particular pharmaceutical company. Participants will be compensated at a fair market value for their time.
 
For more information and for participation instructions click here.

Pages